The biology of chronic foot ulcers in persons with diabetes

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 1, 2008, Pages

  Sibbald, R Gary ^a   Woo, Kevin Y ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Cellular dysfunction; Decreased host resistance; Diabetic foot ulcer; Infection; Neuropeptides; Reactive oxygen species; Wound bed preparation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALPHA 2 MACROGLOBULIN; BETA CATENIN; CALCITONIN GENE RELATED PEPTIDE; GELATINASE A; GELATINASE B; MYC PROTEIN; NERVE GROWTH FACTOR; NEUTROPHIL COLLAGENASE; OXYHEMOGLOBIN; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; SUBSTANCE P; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; CAPILLARY FLOW; CD4 CD8 RATIO; CELL PROLIFERATION; CHEMOTAXIS; COLLAGEN SYNTHESIS; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE EXACERBATION; ENZYME ACTIVITY; HOST RESISTANCE; HUMAN; HYPERGLYCEMIA; IMMUNITY; INFLAMMATION; LEUKOCYTE FUNCTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; TISSUE PERFUSION; WOUND CARE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETIC FOOT; FOOT ULCER; HUMANS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 44949173228     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.847     Document Type: Conference Paper

References (62)

1. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
2. Woo K, Ayello EA, Sibbald RG. The edge effect: current therapeutic options to advance the wound edge. Adv Skin Wound Care 2007; 20(2): 99-117.
3. Ochoa O, Torres FM, Shireman PK. Chemokines and diabetic wound healing. Vascular 2007; 15(6): 350-355.
4. Sibbald RG, Orsted HL, Courts PM, et al. Best practice recommendations for preparing the wound bed: Update 2006. Wound Care Canada 2006; 4(1): R6-R18.
5. Sibbald RG, Orsted HL, Schultz GS, et al. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 2003; 49(11): 24-51.
6. Sibbald RG, Orsted HL, Keast D. Best practice recommendations for preparing the wound bed: update 2006. Adv Skin Wound Care 2007; 20(7): 390-405.
7. Leese GP, Reid F, Green V, et al. Stratiftcation of foot ulcer risk in patients with diabetes: a population-based study. Int J Clin Pract 2006; 60(5): 541-545.
8. Apelqvist J, Larsson J, Agardh CD. The influence of external precipitating factors and peripheral neuropathy on the development and outcome of diabetiC foot ulcers. J Diabet Complications 1990; 4: 1-25.
9. Peters EJ, Armstrong DG, Lavery LA. Risk factors for recurrent diabetic foot ulcers. Diabetes Care 2007; 30(8): 2077-2079.
10. Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care 1999; 22: 692-695.
11. Ince P, Game FL, Jeffcoate WJ. Rate of healing of neuropathic ulcers of the foot in diabetes and its relationship to ulcer duration and ulcer area. Diabetes Care 2007; 30:660-663.
12. Lavery LA, Armstrong DG, Walker SC. Healing rates of diabetic foot ulcers associated with midfoot fracture due to Charcot's arthropy. Diabet Med 1997; 14: 46-49.
13. Oyibo SO, Jude EB, Tarawneh I, et al. The effects of ulcer size and site, patient's age, sex and type on the outcome of diabetic foot ulcers. Diabet Med 2001; 18: 133-138.
14. Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594-608.
15. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006; 22: 257-273.
16. King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004; 122: 333-338.
17. Brownlee M. Negative consequences of glycation. Metabolism 2000; 49(2): 9-13.
18. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46: 223-234.
19. Brownlee MD. Glycation and diabetic complications. Diabetes 1994; 43(6): 836.
20. Inoguchi T, Li P, Umeda F, et al. High Glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependant activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49: 1939-1945.
21. Yagihashi S, Yamagishi SI, Wada R. Pathology and pathogenic mechanisms of diabetic neuropathy: Correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77s: s184-s189.
22. Nishikawa T, Edelstein D, Du XL, et al. Normalising mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-790.
23. Vincent AM, Russell JW, Low P, et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-628.
24. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
25. Rai NK, Tripathi K, Sharma D, et al. Apoptosis: A basic physiologic process in wound healing. Low Extrem Wounds 2005; 4(3): 138-144.
26. Graves DT, Liu R, Alikhani M, et al. Diabetes-enhanced inflammation and apoptosis-impact on Peridontal Pathology. J Dent Res 2006; 85(1): 15-21.
27. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-178.
28. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
29. Loots MAM, Lamme EN, Mekkes JR, et al. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependant diabetes mellitus) show disturbed proliferation. Arch Dermatol Res 1999; 291: 93-99.
30. Mi Q, Riviere B, Clermont G, et al. Agent-based model of inflammation and wound healing: insights into diabetic foot ulcer pathology and the role of transforming growth factor-beta 1. Wound Rep Reg 2007; 15: 671-682.
31. Greenman RJ, Panasyuk S, Wang X, et al. Early changes in the skin microcirculation and muscle metabolism of the diabetic foot. Lancet 2005; 366: 1711-1717.
32. Simonsen I, Holstein P, Larsen K, et al. Glucose metabolism in chronic diabetic foot ulcers measured in vivo using microdialysis. Clin Physiol 1998; 18(4): 355-359.
33. Stolle LB, Nielsen PR. The metabolism if the diabetic foot. In vivo investigation with microdialysis. Acta Orthop Scand 2004; 75(1): 106-108.
34. Brem. H, Stojadinovic O, Diegelmann RF. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med 2007; 13(1-2): 30-39.
35. Stojadinovic O, Brem H, Vouthounis C, et al. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialisation and wound healing. Am J Pathol 2005; 167: 59-69.
36. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-285.
37. Ganea E, Trifan M, Laslo AC, et al. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007; 35(4) 689-691.
38. Moseley R, Stewart JE, Stephens P, et al. Extracellular matrix metabolites as potential biomarkers of disease activity in wound fluid: lessons learned from other inflammatory diseases? Br J Dermatol 2004, 150: 401-413.
39. Cawston TE, Wilson AJ. Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006; 20(5): 983-1002.
40. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
41. Trengove NJ, Stacey MC, Fracs DS, et al. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors. Wound Rep Reg 1999; 7: 442-452.
42. Pierce GF. Inflammation in nonhealing diabetic wounds, the space-time continuum does matter. Am J Pathol 2001; 159(2): 399-403.
43. Lobmann R, Ambrosch A, Schultz G, et al. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002; 45: 1011-1016.
44. Lohmann R, Zemin C, Motzkau M, et al. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complicat 2006; 20: 329-335.
45. Harding KG, Moore K, Phillips TJ. Wound chronicity and fibroblast senescence-implications for treatment. Int Wound J 2005; 2(4): 364-368.
46. Calhoun JH, Overgaard KA, Stevens CM, et al. Diabetic foot ulcers and infections: current concepts. Adv Skin Wound Care 2002; 15: 31-45.
47. Mowat A, Baum J. Chemotaxis of polymorphonuclear leucocytes from patients with diabetes mellitus. N Engl J Med 1971; 284(12): 621-627.
48. Galkowska H, Wojewodzka U, Olszewski WL. Low recruitment of immune cells with increased expression of endothelial adhesion molecules in margins of the chronic diabetic foot ulcers. Wound Rep Reg 2005; 13: 248-254.
49. Loots MAM, Lamme EN, Zeeglar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998; 111: 850-857.
50. Breslin RJ, Wasserkrug HL, Efron BAG, et al. A suppressor cell generation during normal wound healing. J Surg Res 1988; 44: 321-325.
51. Barbul A, Regan MC. The regulatory role of T-Lymphocytes in wound healing: part II. Role in normal and chronic wound healing. J Trauma 1990; 30(Suppl. 12): 97-100.
52. Sibbald RG, Woo K, Ayello EA. Increased bacterial burden and infection: The story of NERDS and STONES. Adv Skin Wound Care 2006; 19(8): 447-461.
53. Landis S, Ryan S, Woo K, et al. Infections in chronic wounds. Chronic Wound Care: A Clinical Source Book For Healthcare Professionals (4th edn), 2007; (HMP Communications), 299-321.
54. Galkowska H, Olszewski WL, Wojewodzka U, et al. Neurogenic factors in the impaired healing of diabetic foot ulcers. J Surg Res 2006; 134: 252-258.
55. Quattrini C, Jeziorska M, Malik RA. Small fibre neuropathy in diabetes: clinical consequence and assessment. Int J Low Extrem Wounds 2004; 3(1): 16-21.
56. Richards AM, Mitsou J, Floyd DC, et al. Neural innervation and healing. Lancet 1997; 350: 330-340.
57. Smith PG, Liu M. Impaired cutaneous wound healing after sensory denervation in developing rats: effects on cell proliferation and apoptosis. Cell Tissue Res 2002; 307: 281-291.
58. Meerwaldt R, Links TP, Graaf R. Increased accumulation of skin advanced glycation end products precedes and correlates with clinical manifestations of diabetic neuropathy. Diabetologia 2005; 48: 1637-1644.
59. Antezana MA, Sullivan SR, Usui ML, et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic foot ulcers. J Invest Dermatol 2002; 119: 1400-1404.
60. Jorneskog G, Brismar K, Fagrell B. Skin capillary circulation is more impaired in toes of diabetic than non-diabetic patients with peripheral vascular disease. Diabet Med 1995; 12: 36-41.
61. Nelson EA, O'Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess 2006; 10(12): iii-iiv, ix-ix, 1-221.
62. Woo K, Alavi A, Botros M, et al. A transprofessional comprehensive assessment model for persons with lower extremity leg and foot ulcers. Wound Care Canada 2007; 5(1): Suppl. s34-s47.